[HTML][HTML] COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
…, M Fittall, M Tilby, M Rowe, M Alihilali, M Galazi… - The Lancet …, 2020 - thelancet.com
Background Patients with cancer are purported to have poor COVID-19 outcomes. However,
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …
Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer
…, JS Evans, N Saoudi-Gonzalez, E Felip, M Galazi… - Cancer discovery, 2020 - AACR
In this observational study of 890 patients with cancer diagnosed with SARS-CoV-2, mortality
was 33.6% and predicted by male gender, age ≥65, and comorbidity burden. Delivery of …
was 33.6% and predicted by male gender, age ≥65, and comorbidity burden. Delivery of …
Outcomes of the SARS-CoV-2 omicron (B. 1.1. 529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the …
Background The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and
escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during …
escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during …
Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19
…, A Wu, D Ottaviani, G Soosaipillai, M Galazi… - JAMA network …, 2022 - jamanetwork.com
Importance Large cohorts of patients with active cancers and COVID-19 infection are needed
to provide evidence of the association of recent cancer treatment and cancer type with …
to provide evidence of the association of recent cancer treatment and cancer type with …
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the …
Background The medium-term and long-term impact of COVID-19 in patients with cancer is
not yet known. In this study, we aimed to describe the prevalence of COVID-19 sequelae and …
not yet known. In this study, we aimed to describe the prevalence of COVID-19 sequelae and …
[HTML][HTML] Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe
…, N Chopra, CA Cruz, F D'Avanzo, JS Evans, M Galazi… - Cancers, 2020 - mdpi.com
We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in
Europe from the retrospective, multi-center observational OnCovid study. We identified 204 …
Europe from the retrospective, multi-center observational OnCovid study. We identified 204 …
Proteomic biomarkers of endometrial cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration
N Galazis, YL Pang, M Galazi, Z Haoula… - Gynecological …, 2013 - Taylor & Francis
There is a need for research studies into the molecular mechanisms underpinning the link
between polycystic ovary syndrome (PCOS) and endometrial cancer (EC) to facilitate …
between polycystic ovary syndrome (PCOS) and endometrial cancer (EC) to facilitate …
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
A Rodriguez-Vida, M Galazi, S Rudman… - Drug design …, 2015 - Taylor & Francis
In recent years, several nonhormonal and hormonal agents, including enzalutamide, have
been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on …
been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on …
[HTML][HTML] Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study
…, J Aguilar-Company, M Bower, M Galazi… - European Journal of …, 2021 - Elsevier
Background Despite high contagiousness and rapid spread, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected …
syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected …
[HTML][HTML] INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction …
Background Whilst multi-parametric magnetic resonance imaging (mp-MRI) has been a
significant advance in the diagnosis of prostate cancer, scanning all patients with elevated …
significant advance in the diagnosis of prostate cancer, scanning all patients with elevated …